BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Vustanaciclib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Vustanaciclib\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05304962-9089@assetmemo.bio
DTSTAMP:20261121T004533Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Vustanaciclib: Phase 1 readout est. (NCT05304962)
DESCRIPTION:Vustanaciclib\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positi
 ve\, HER2-Negative Advanced/Metastatic Breast Cancer\nEstimated primary co
 mpletion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/vustanaciclib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT05304962
URL:https://assetmemo.bio/drug/vustanaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06299124-9089@assetmemo.bio
DTSTAMP:20261121T004533Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Vustanaciclib: Phase 1 readout est. (NCT06299124)
DESCRIPTION:Vustanaciclib\, phase 1\, HR+/HER2- Metastatic Breast Cancer.\n
 Study: A Phase I Study of RGT-419B in Patients With HR-Positive\, HER2-Neg
 ative Advanced Breast Cancer or Other Solid Tumors\nEstimated primary comp
 letion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/vustanaciclib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06299124
URL:https://assetmemo.bio/drug/vustanaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07100106-9089@assetmemo.bio
DTSTAMP:20261121T004533Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Vustanaciclib: Phase 1/2 readout est. (NCT07100106)
DESCRIPTION:Vustanaciclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.
 \nStudy: A Study to Evaluate the Effect of GDC-4198 Alone and in Combinati
 on With Giredestrant Versus Abemaciclib and Giredestrant in Participants W
 ith Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+)\, Huma
 n Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer\nEstimat
 ed primary completion: 31 August 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/vustanaciclib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07100106
URL:https://assetmemo.bio/drug/vustanaciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
